Business
Nuwellis Receives FDA 510(k) Clearance for New Dual Lumen Extended Length Catheter
MINNEAPOLIS, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on fluid management, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for a new size of its Dual Lumen Extended Length Catheter (dELC). Advancing a broader fluid management platform: This clearance supports Nuwellis’ multi-year plan to build a comprehensive fluid management platform—combining therapy delivery, dedicated venous access, and prac
About this update from Nuwellis, Inc.
[{"type":"image","alt":"Nuwellis, Inc.","displaySize":"","headline":null,"caption":"Nuwellis, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":72,"url":"https://media.zenfs.com/en/globenewswire.com/d2460037586c5d451999b7d63383d34b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/epm_zxode7LAVlWVBg62FQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/d2460037586c5d451999b7d63383d34b","width":300,"height":72}},"lazy":false},{"type":"text","content":"MINNEAPOLIS, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on fluid management, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for a new size of its Dual Lumen Extended Length Catheter (dELC).","length":290,"tagName":"p"},{"type":"text","content":"Advancing a broader fluid management platform:","length":46,"tagName":"p"},{"type":"text","content":"This clearance supports Nuwellis’ multi-year plan to build a comprehensive fluid management platform—combining therapy delivery, dedicated venous access, and practical implementation support—so hospitals and clinics can standardize how they identify patients, begin ultrafiltration therapy earlier, and sustain programs from the ICU to step-down and hospital-based outpatient settings. The company’s strategy centers on three growth drivers: critical care, cardiac surgery recovery, and hospital-based outpatient heart failure programs.","length":536,"tagName":"p"},{"type":"text","content":"“Clinicians have asked for dependable peripheral access that works across inpatient units and emerging outpatient programs,” said John Erb, Chief Executive Officer of Nuwellis. “With two extended lengths and coil reinforcement, the dELC helps teams match access to the patient and care setting, streamlining workflow, and delivering therapy with increased confidence. This new length is another step in strengthening our technology platform and enabling consistent, repeatable use of Aquadex across care pathways.”","length":514,"tagName":"p"},{"type":"text","content":"Why it matters for clinicians:","length":30,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Peripheral access, central-line performance — Coil reinforcement and dual-lumen design enable consistent blood flow for ultraf...